Every material Form 8-K MoonLake Immunotherapeutics has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MoonLake reported third quarter 2026 results and a business update, including submission of a Biologics License Application for sonelokimab in hidradenitis suppurativa on September 30, 2026. Research and development expenses rose to $68.9 million, mainly from accrued milestone license fees tied to the expected BLA acceptance, while the company reported cash, cash equivalents and short-term marketable debt securities of $498.5 million and a cash runway to mid-2028. The filing does not report revenue or earnings per share.
R&D expenses were $68.9 million for the quarter ended September 30, 2026, up $18.7 million from $50.2 million in the prior quarter, mainly from accrued milestone license fees.
G&A expenses were $11.0 million, compared with $11.4 million in the prior quarter.
Cash and short-term marketable debt securities were $498.5 million as of September 30, 2026, with a cash runway expected to mid-2028.
The company expects a decision on BLA acceptance by the end of November 2026 and up to $400 million more is available through its Hercules Capital debt facility.
MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.
BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
FDA acceptance decision expected within approximately 60 days of submission
Planned review timeline expected from the FDA within approximately 74 days of submission
MoonLake Immunotherapeutics reported positive topline Week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in biologic-naive psoriatic arthritis patients, with 42.1% of patients on the 60 mg induction dose achieving an ACR50 response. The company also reported second quarter 2026 results, with cash of $537.0 million and a stated cash runway to mid-2028, and the filing notes that comparisons against placebo remain blinded until the Phase 3 program is complete.
IZAR-1 met all clinical endpoints at Week 16 for the 60 mg sonelokimab arm; 42.1% achieved ACR50 and 66.5% achieved ACR20.
Research and development expenses were $50.2 million in the quarter ended June 30, 2026, down from $54.5 million in the prior quarter; general and administrative expenses were $11.4 million, down from $15.5 million.
Cash, cash equivalents and short-term marketable debt securities were $537.0 million as of June 30, 2026; up to $400 million more is available through a Hercules Capital debt facility.
The IZAR-1 trial remains blinded and continues to Week 52, with the full readout expected in H1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MoonLake Immunotherapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →